Health and Medical Research National Institute, Research Unit 669, Paris, France.
Harm Reduct J. 2008 May 21;5:17. doi: 10.1186/1477-7517-5-17.
Despite France being regarded as a model of efficient harm reduction policy and equity of access to care in the general community, the health of French inmates is a critical issue, as harm reduction measures are either inaccessible or only partially implemented in French prisons.
Using specific inclusion and exclusion criteria, information was collected and analyzed about HIV, HBV and HCV prevalence, risk practices, mortality, access to harm reduction measures and care for French prison inmates.
Data about the occurrence of bloodborne diseases, drug use and access to care in prisons remain limited and need urgent updating. Needle exchange programs are not yet available in French prisons and harm reduction interventions and access to OST remain limited or are heterogeneous across prisons. The continuity of care at prison entry and after release remains problematic and should be among the primary public health priorities for French prisoners.
Preventive and harm reduction measures should be urgently introduced at least as pilot programs. The implementation of such measures, not yet available in French prisons, is not only a human right for prison inmates but can also provide important public health benefits for the general population.
尽管法国被认为是在减少伤害和公平获得医疗方面的一个有效政策和公平性的典范,但法国囚犯的健康仍然是一个关键问题,因为减少伤害的措施在法国监狱中无法获得或仅部分实施。
使用特定的纳入和排除标准,收集和分析了有关法国监狱囚犯中 HIV、HBV 和 HCV 患病率、风险行为、死亡率、获得减少伤害措施和护理的信息。
关于监狱中发生的血液传播疾病、药物使用和获得护理的数据仍然有限,需要紧急更新。法国监狱中还没有提供针具交换计划,减少伤害的干预措施和获得 OST 的机会仍然有限或在不同监狱之间存在差异。在监狱进入和释放后的护理连续性仍然存在问题,应该成为法国囚犯的主要公共卫生优先事项之一。
应紧急引入预防和减少伤害的措施,至少作为试点项目。在法国监狱中尚未实施的这些措施的实施不仅是囚犯的一项人权,而且还可以为普通民众提供重要的公共卫生益处。